Stocks to Watch: Gemini Explorations, Inc. (OTCBB: GXPI), OncoVista, Inc (OTC BB:AVUG.OB) , Aida Pharmaceuticals, Inc. (OTC BB:AIDA) , eFoodSafety.com (OTC BB:EFSF) , Edgeline Holdings, Inc. (OTC BB:ELHI)
Featured Stock: Gemini Explorations, Inc.
(OTCBB: GXPI)
Current Price (0.11)
http://www.wallstreetstockreview.com/
GEMINI EXPLORATIONS COMMENCES MODERNIZATION OF THE LOS CHORROS GOLD MINE
~Mine modernization projected to yield US$12,900,000 of net cash flow to Gemini~
The Los Chorros Mine is currently being mined with extremely antiquated equipment and this report further solidifies Gemini’s belief that the project could be turned into a highly efficient producing gold project with low capital costs. Current mining operations at Los Chorros recover a low percentage of the available gold and precious metals present on the property. The plant would initially run at 30 to 50 tonnes/day with a targeted production rate of 100 tonnes per day during the first year. Minera Primecap Geological Services (MPGS) reported that a 100 tonne per day production rate would produce US$1,080,280 monthly and over US$12,900,000 annually. These estimates are based on US$730 per ounce gold with US$200 per ounce operating and production costs netting US$530 per ounce.
Historically one of the largest gold producing countries in the world,
Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the expectation of the gold production of the property, the expected completion date of the redevelopment and modernization of the Los Chorros Gold mine and the low capital costs to upgrade the Los Chorros operating plant and the net cash flow estimates.Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the 2006 fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Michael Hill
President
Gemini Explorations, Inc
http://www.geminiexploration.com/ email: info@geminiexploration.com
403-697-4877
For an in-depth analyst report, please visit: http://www.wallstreetstockreview.com/
OncoVista, Inc
(OTC BB:AVUG.OB)
Current Price (2.50)
http://www.wallstreetstockreview.com/
SAN ANTONIO--Dec 5--OncoVista, Inc., (OTC BB: AVUG - News) a biopharmaceutical company dedicated to development of innovative, safe and efficacious treatments for cancer, today announced that it has retained Porter, LeVay & Rose as its investor relations agency. OncoVista is a biopharmaceutical company engaged in the development and rapid commercialization of innovative targeted therapies for safe and efficacious treatment of cancer. For more information, please visit http://www.oncovista.com
Aida Pharmaceuticals, Inc.
(OTC BB:AIDA)
Current Price (1.23)
http://www.wallstreetstockreview.com/
SANTA MONICA, Calif., Dec. 4 - Aida Pharmaceuticals (OTC Bulletin Board: AIDA - News) today announced that the company's upcoming Rh-Apo2L cancer drug has been named as a "New and High-Tech Transforming Products of 2007" by the Shanghai New High Technology Service Centre ("SNHTSC"), a special government commercialization division led by the Shanghai Municipal Government. This designation will allow Rh-Apo2L to have preferential policies during the commercialization process after Aida completes
eFoodSafety.com
(OTC BB:EFSF)
Current Price (0.24)
http://www.wallstreetstockreview.com/
SCOTTSDALE, Ariz.--Dec 5--eFoodSafety.com, Inc. (OTCBB:EFSF - News) today announced that its wholly owned subsidiary Knock-Out Technologies, Ltd. will begin a dual purpose study to determine the effectiveness of Citroxin™, using a trans-dermal vehicle, against Methicillin Resistant Staphylococcus Aureus (MRSA). This test is the next progressive step following successful testing of Citroxin™ that demonstrated positive results for eradicating MRSA in a laboratory setting. This step is coupled with the recent completion of a unique trans-dermal cream containing Citroxin™ as the active ingredient. eFoodSafety.com, Inc., through its subsidiaries, offers technologies that enhance food and health conditions. It develops various products, including anthrax sporicidal, a germicidal cleaner, a wound care antiseptic, an herbicide, and an insect repellent. The company also distributes various products to physicians who then prescribe the products for their patients. It primarily distributes Talsyn-CI/bid scar cream that facilitates and improves the appearance, redness, and strength of scars; Cinnergen, a non prescription liquid whole food nutritional supplement that promotes glucose metabolism; and Trimmendous, a weight loss formula focusing on the body's 24-hour metabolic processes. eFoodSafety.com markets its products in the
Edgeline Holdings, Inc.
(OTC BB:ELHI)
Current Price (0.40)
http://www.wallstreetstockreview.com/
HOUSTON--Dec 5--Edgeline Holdings, Inc. (OTCBB:ELHI) announced today that it has signed an Option agreement with The University of Texas M. D. Anderson Cancer Center that provides Edgeline Holdings the exclusive right to negotiate a license to five technologies relating to the treatment of various cancers over a nine month period. During this period the company has the right to evaluate the patents rights, potential products and markets, and to negotiate a license for the use of these patents. Headquartered in
Penny Stocks traded in the Small Cap Markets who seek Investor Relations, can receive complete coverage from WallstreetStockReview.com. WallstreetStockReview.com covers Penny Stock analyst reports and strives to keep the Penny Stock Investor updated. It is essential that the smallcap stock investor stay informed when making decisions through Penny Stock analyst reports. Visitors can sign up for our penny stock newsletter and analyst reports, to be kept up to date when we begin coverage on new small cap companies. Coverage of micro cap stock Companies and Penny Stock analyst reports are provided by WallstreetStockReview.com. Sign up today and stay informed of your Investment, allow WallstreetStockReview.com to provide you with the latest analyst reports on small cap and pennystocks.
WallStreetStockReview.com is owned and operated by Iron Consulting.
Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering secu rities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.